A-type voltage-gated potassium channel KCND3

BE0003604ProteinHumansKCND3

Pore-forming (alpha) subunit of voltage-gated A-type potassium channels that mediates transmembrane potassium transport in excitable membranes, in brain and heart (PubMed:10200233, PubMed:17187064, PubMed:21349352, PubMed:22457051, PubMed:23280837, PubMed:23280838, PubMed:34997220, PubMed:9843794). It is acted on by 11 drugs in DrugBank.

Gene name
KCND3
UniProtKB entry
Q9UK17Swiss-Prot
Cellular location
Cell membrane
Residues / weight
655 residues · 73,451 Da
Also known as
Potassium voltage-gated channel subfamily D member 3 · Voltage-gated potassium channel subunit Kv4.3

Resolves to

Protein
UniProtQ9UK17UniProt nameKCND3_HUMAN
Gene
HGNCHGNC:6239NCBI Gene3752GenBank2935434GeneCardsKCND3
Pharmacology
KEGGhsa:3752
Structure
PDB1S1GPDB2NZ0PDB7W3Y
Drugs

What you can answer from here — as of September 03, 2024

11DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
7GO termsFunction, process and component, as structured annotations
Sign in
4Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
28+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on A-type voltage-gated potassium channel KCND3, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In